- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03054389
Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews
April 21, 2021 updated by: Baxalta now part of Shire
The purpose of this study is to seek to understand the patient's perspective around deciding to participate in a clinical trial for a Hemophilia therapy
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
27
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02139
- QuintilesIMS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Investigators, Study Coordinators, and Participants from the AskBio009-101 Study
Description
Inclusion criteria for patients:
- Were screened and consented for the AskBio009-101study at any point in time
- Are able to speak and understand English
- Are between ages of 18 and 75
- Are physically able to participate in a one-hour phone interview
- Consented into this study independently of the AskBio009-101 study
Exclusion criteria for patients:
- N/A
Inclusion criteria for investigators and coordinators:
- Worked at a site as an investigator or study coordinator that consented a patient into the
- AskBio009-101 trial at any point in time, including those that no longer work at a AskBio009-101 site
- Are able to speak and understand English
- Are between ages of 18 and 75
- Are physically able to participate in a one-hour phone interview
Exclusion criteria for investigators and coordinators:
- Not directly involved in the consent process at the gene therapy site
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Participants/ Patients
Participants/ Patients from the AskBio009-101 Study
|
Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
|
|
Investigators and Study Coordinators
Investigators and Study Coordinators from the AskBio009-101 Study
|
Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interview - AskBio009-101 Study - Participants/ Patients
Time Frame: Approximately 1 hour
|
Qualitative telephone interviews to understand the patient experience with the AskBio009-101 Study - Participant/ Patient Interview
|
Approximately 1 hour
|
|
Interview - AskBio009-101 Study - Investigators and Study Coordinators
Time Frame: Approximately 1 hour
|
Qualitative telephone interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators Interview
|
Approximately 1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2017
Primary Completion (Actual)
June 6, 2017
Study Completion (Actual)
June 6, 2017
Study Registration Dates
First Submitted
February 13, 2017
First Submitted That Met QC Criteria
February 13, 2017
First Posted (Actual)
February 15, 2017
Study Record Updates
Last Update Posted (Actual)
April 23, 2021
Last Update Submitted That Met QC Criteria
April 21, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia B
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
BayerCompletedHemophilia A; Hemophilia BIsrael
-
ApcinteX LtdCentessa Pharmaceuticals plcTerminatedHemophilia B | Hemophilia a | Hemophilia a with Inhibitor | Hemophilia B with InhibitorGeorgia, Moldova, Republic of
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
American Thrombosis and Hemostasis NetworkGenentech, Inc.CompletedHemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Laboratoire français de Fractionnement et de BiotechnologiesLFB USA, Inc.CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With InhibitorsBulgaria, Ukraine, Czechia, United States, Georgia, South Africa
-
University College, LondonRecruiting
-
University of British ColumbiaBiogenCompletedHemophilia A, Congenital | Hemophilia B, CongenitalCanada
-
Suzhou Alphamab Co., Ltd.Not yet recruiting
-
Suzhou Alphamab Co., Ltd.Active, not recruitingHemophilia A With Inhibitor | Hemophilia B With InhibitorChina
Clinical Trials on Qualitative Interview - Participants/ Patients
-
University of ExeterUniversity of Nottingham; University of Bristol; National Institute for Health...Completed
-
UNC Lineberger Comprehensive Cancer CenterDoris Duke Charitable Foundation; Conquer Cancer FoundationCompleted
-
Manchester Academic Health Science CentreKing's College London; Cardiff University; University of Edinburgh; University... and other collaboratorsCompletedSchizophrenia | Schizoaffective Disorder | PsychosisUnited Kingdom
-
ARCIM Institute Academic Research in Complementary...Completed
-
University Hospital Center of MartiniqueKaFE Association (Karaib Formation Etudes)Not yet recruitingCancer | Oncology | Oncologic DiseasesMartinique
-
University Hospital Southampton NHS Foundation...Recruiting
-
Centre Hospitalier Universitaire de BesanconCompletedAging | Euthanasia | Assisted Suicide | Qualitative ResearchFrance
-
King's College LondonPrincess Alice HospiceCompleted
-
HaemnetUniQure Biopharma B.V.Completed
-
University of OxfordCompleted